Table 1. Ongoing and historical clinical trials that target tryptophan catabolism in cancer.
Clinical trials were identified on the website clinicaltrials.gov as of 07/15/2015.
| Agent | Indication(s) | Phase | Status | Notes | Identifier |
|---|---|---|---|---|---|
| Indoximod (D- 1-MT) | Metastatic solid tumor | I | Completed | Combined with docetaxel | NCT01191216 |
| Solid Tumor | I | Completed | Single Agent | NCT00567931 | |
| I | Terminated | Single Agent | NCT00739609 | ||
| Malignant glioma | I/II | Recruiting | For recurrent glioma patients | NCT02052648 | |
| Metastatic Breast Cancer | I/II | Active, not recruiting | Combined with vaccine | NCT01042535 | |
| II | Recruiting | Combined with docetaxel | NCT01792050 | ||
| Melanoma | I/II | Recruiting | Combined with ipilimumab | NCT02073123 | |
| Metastatic Adenoma of Pancreas | I/II | Recruiting | Combined with gemcitabine and nab-paclitaxel | NCT02077881 | |
| Prostate carcinoma | II | Recruiting | Combined with sipuleucel-T | NCT01560923 | |
| NSCLC | II | Not yet recruiting | Combined with docetaxel and tergenpumatucel-L | NCT02460367 | |
| INCB024360 | Advanced neoplasms | I | Completed | As single agent | NCT01195311 |
| Myelodysplastic Syndromes | II | Active, not recruiting | As single agent | NCT01822691 | |
| Melanoma | I/II | Recruiting | Combined with ipilimumab | NCT01604889 | |
| II | Recruiting | Combined with a multipeptide-based vaccine | NCT01961115 | ||
| Reproductive tract tumors | II | Completed | Compared to tamoxifen | NCT01685255 | |
| I | Recruiting | As single agent | NCT02042430 | ||
| I/II | Withdrawn | Combined with vaccine therapy | NCT01982487 | ||
| I | Recruiting | Combined with adoptive transfer of NK cells and IL-2 | NCT02118285 | ||
| I/II | Recruiting | Combined with DC-targeted NY-ESO-1 and poly-ICLC | NCT02166905 | ||
| Solid tumors | I/II | Recruiting | Combined with a PDCD1 mAb | NCT02178722 | |
| I/II | Recruiting | Combined with MEDI4736 (PD-L1 mAb) | NCT02318277 | ||
| Prev. Tx NSCLC | I | Recruiting | Combined with MPDL3280A (PD-L1 mAb) | NCT02298153 | |
| GDC-0919 (formerly NLG-919) | Solid tumors | I | Recruiting | Single agent | NCT02048709 |
| Locally-advanced or metastatic solid tumors | I | Not yet open | Combined with MPDL3280A (PD-L1 mAb) | NCT02471846 | |
| IDO1 peptide | NSCLC | I | Completed | As single agent | NCT01219348 |
| Melanoma | I | Recruiting | Combined with ipilimumab or vemurafenib | NCT02077114 | |
| Melanoma | II | Recruiting | Combined with temozolomide, imiquimod, GM-CSF and survivin peptide | NCT01543464 |